Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Genvoya

02 5Prezista/Prezcobix/Rezolsta/Symtuza

03 2Revenue share - Symtuza

04 10Stribild

05 3Symtuza

PharmaCompass

01

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
Arvo
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
Arvo
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,184

2019 Revenue in Millions : 2,110

Growth (%) : 4

blank

02

arrow
Arvo
Not Confirmed

03

arrow
Arvo
Not Confirmed

04

arrow
AOCS Annual Meeting
Not Confirmed

Brand Name : Stribild

arrow
AOCS Annual Meeting
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 196

2019 Revenue in Millions : 369

Growth (%) : -47

blank

05

arrow
Arvo
Not Confirmed

06

arrow
Arvo
Not Confirmed

07

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
Arvo
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
Arvo
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,083

2020 Revenue in Millions : 2,184

Growth (%) : -5

blank

08

arrow
Arvo
Not Confirmed

09

arrow
Arvo
Not Confirmed

10

arrow
Arvo
Not Confirmed